Olamkicept

奥拉奇西普

Report date: 2025/12/21 20:00:08

Base Information

Drug NameOlamkicept
Drug Alias Name奥拉西普奥兰吉西普TJ-301FE-999301CR-5/18 +[6] 
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion protein > Fc fusion protein
Mechanisms of ActionInterleukin-6 receptor alpha subunit antagonistsInterleukin-6 receptor subunit beta antagonists
TargetsInterleukin-6 receptor alpha subunitInterleukin-6 receptor subunit beta
Therapy Area/IndicationsColitis, UlcerativeGastrointestinal Diseases
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryTaiwanSouth KoreaMainland China +[4] 
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesConaris Research Institute
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesFerring BvTJ Biopharma(Hangzhou) Co Ltd
Inactive CompaniesI-Mab Biopharma Hongkong LtdLeading Biopharm LtdI-Mab Biopharma Co Ltd +[4] 
Active IndicationsColitis, UlcerativeGastrointestinal Diseases
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A